Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.

Abstract

BACKGROUND:

Olopatadine 0.2% is the first topical ophthalmic antihistamine/mast cell stabilizer indicated for once-daily dosing.

OBJECTIVE:

This review provides a comprehensive description of the pharmacology of the olopatadine molecule, as well as of the clinical efficacy, tolerability, and safety of olopatadine 0.2% ophthalmic solution.

METHODS:

References cited in this review were obtained from the PubMed biomedical literature database. Also included were several posters presented at nationally renowned ophthalmology-related conferences.

RESULTS/CONCLUSION:

Olopatadine 0.2% was found to be a safe and effective medication for the reduction of itching with a duration of action of up to 24 h. The added convenience of a once-a-day dosing regimen is a major advancement in this drug class.

• Authors: Mark B Abelson, Paul J Gomes
• Journal: Expert opinion on drug metabolism & toxicology (Expert Opin Drug Metab Toxicol) Vol. 4 Issue 4 Pg. 453-61 (Apr 2008) ISSN: 1742-5255 [Print] England
• PMID: 18433347 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Allergic Agents
• Dibenzoxepins
• Histamine H1 Antagonists, Non-Sedating
• Ophthalmic Solutions
• Olopatadine Hydrochloride

Topics

• Anti-Allergic Agents (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Conjunctivitis, Allergic (drug therapy, physiopathology)
• Dibenzoxepins (adverse effects, therapeutic use)
• Histamine H1 Antagonists, Non-Sedating (adverse effects, therapeutic use)
• Humans
• Olopatadine Hydrochloride
• Ophthalmic Solutions (adverse effects, therapeutic use)
• Treatment Outcome